Skip to content
value.today

Vivace Therapeutics, Inc.

🇺🇸 Orinda, California, USAPharmaceuticalsFounded 2014
Total raised
$61 M
4 rounds on record
Latest round
$18 M
Feb 2025
First round on record
Jan 2015
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Vivace Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2025$18 MNo. 4$10 to $50 million

Vivace Therapeutics, Inc.: Raise no. 4, Feb 2025

Investors in this round

5 investors had bought by the notice of Mar 12, 2025: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $35 M offered; $18 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shuang Qiao · Executive Officer, Director
  • Chenguang Zhou · Director
  • Edward Hu · Director
  • Jake Simson · Director
  • Jun Wu · Director
  • Tim Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Shares of Series D Preferred Stock, and the Common Stock issuable upon conversion thereof.”

Signed by Shuang Qiao, Chief Executive Officer. Newest notice filed Mar 12, 2025. Read the notice at the SEC.

equitySEC
Dec 2020$30 MNo. 3$10 to $50 million

Vivace Therapeutics, Inc.: Raise no. 3, Dec 2020

Investors in this round

6 investors had bought by the notice of Dec 23, 2020: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shuang Qiao · Executive Officer, Director
  • Chenguang Zhou · Director
  • Edward Hu · Director
  • Jun Wu · Director
  • Leonard Post · Director
  • Tim Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shuang Qiao, President & CEO. Newest notice filed Dec 23, 2020. Read the notice at the SEC.

equitySEC
May 2017$8 MNo. 2$2 to $10 million

Vivace Therapeutics, Inc.: Raise no. 2, May 2017

Investors in this round

6 investors had bought by the notice of May 1, 2018: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $25 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Leonard Post · Executive Officer, Director
  • Shuang Qiao · Executive Officer, Director
  • Edward Hu · Director
  • Jun Wu · Director
  • Tim Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shuang Qiao, President & CEO. Newest notice filed May 1, 2018 (1 amendment). Read the notice at the SEC.

equitySEC
Jan 2015$5 MNo. 1$2 to $10 million

Vivace Therapeutics, Inc.: Raise no. 1, Jan 2015

Investors in this round

3 investors had bought by the notice of Jan 20, 2015: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $15 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Sheng Ding · Executive Officer
  • Shuang Qiao · Executive Officer, Director
  • Edward Hu · Director
  • Tim Shannon · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Shuang Qiao, President & CEO. Newest notice filed Jan 20, 2015. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Vivace Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2025).

    SEC Form D · Mar 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2025

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Vivace Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Vivace Therapeutics, Inc.
NameRoleNamed in
Shuang QiaoExecutive officerMar 2025
Leonard PostExecutive officerMay 2018
Sheng DingExecutive officerJan 2015
Chenguang ZhouDirectorMar 2025
Edward HuDirectorMar 2025
Jake SimsonDirectorMar 2025
Jun WuDirectorMar 2025
Shuang QiaoDirectorMar 2025
Tim ShannonDirectorMar 2025
Leonard PostDirectorDec 2020